Julien Lefranc

Frankfurter Str. 250
Darmstadt, HE 64293, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1.

Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1.

Journal: Journal of medicinal chemistry
Published: December 08, 2025

Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Journal: Journal of medicinal chemistry
Published: September 17, 2025

Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Journal: Nucleic acids research
Published: June 27, 2025

Intramolecular Lithiation-Borylation for the Stereoselective Synthesis of Cyclopentyl and Cyclobutyl Bis-Boronic Esters.

Intramolecular Lithiation-Borylation for the Stereoselective Synthesis of Cyclopentyl and Cyclobutyl Bis-Boronic Esters.

Journal: Angewandte Chemie (International ed. in English)
Published: June 12, 2025

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.

Journal: Journal for immunotherapy of cancer
Published: October 08, 2023

Back in Person: Frontiers in Medicinal Chemistry 2023.

Back in Person: Frontiers in Medicinal Chemistry 2023.

Journal: ChemMedChem
Published: July 06, 2023

Frontiers in Medicinal Chemistry 2022 Goes Virtual.

Frontiers in Medicinal Chemistry 2022 Goes Virtual.

Journal: ChemMedChem
Published: July 30, 2022

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

Journal: Cellular oncology (Dordrecht, Netherlands)
Published: December 16, 2020

Nickel-Catalyzed N-Arylation of NH-Sulfoximines with Aryl Halides via Paired Electrolysis.

Nickel-Catalyzed N-Arylation of NH-Sulfoximines with Aryl Halides via Paired Electrolysis.

Journal: Angewandte Chemie (International ed. in English)
Published: December 08, 2020

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

Journal: Journal of medicinal chemistry
Published: June 06, 2020

Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.

Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.

Journal: Journal of medicinal chemistry
Published: December 21, 2019

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.

Journal: Molecular cancer therapeutics
Published: January 14, 2019
Showing 1-12 of 14

Last Updated: 09/26/2026